{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T01:12:19Z","timestamp":1752282739489,"version":"3.41.0"},"reference-count":31,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2025,5,31]]},"DOI":"10.1536\/ihj.24-698","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T22:08:40Z","timestamp":1748642920000},"page":"443-448","source":"Crossref","is-referenced-by-count":1,"title":["High Prevalence of Thyroid Gland Dysfunction after Pulmonary Arterial Hypertension Treatment According to Real-World Data"],"prefix":"10.1536","volume":"66","author":[{"given":"Noriaki","family":"Takama","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Ishibashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University School of Medicine"},{"name":"Department of Cardiovascular Medicine, Kyorin University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Batgerel","family":"Naidankhoo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syunichiro","family":"Ishio","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumitaka","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Yuasa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukie","family":"Sano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Amanai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemi","family":"Sorimachi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimitsu","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Laboratory of Diabetes and Metabolic Disorders, Institute for Molecular and Cellular Regulation, Gunma University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nagasaka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Obokata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norimichi","family":"Koitabashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Humbert M, Kovacs G, Hoeper MM, <i>et al<\/i>. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43: 3618-31.","DOI":"10.1093\/eurheartj\/ehac237"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Pulido T, Adzerikho I, Channick RN, <i>et al<\/i>. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809-18.","DOI":"10.1056\/NEJMoa1213917"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gali\u00e8 N, Barber\u00e0 JA, Frost AE, <i>et al<\/i>. Initial use of Ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834-44.","DOI":"10.1056\/NEJMoa1413687"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ogo T, Shimokawahara H, Kinoshita H, <i>et al<\/i>. Selexipag for the treatment of chronic thromboembolic pulmonary hypertension. Eur Respir J 2022; 60: 2101694.","DOI":"10.1183\/13993003.01694-2021"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Fukuda K, Date H, Doi S, <i>et al<\/i>. Guidelines for the treatment of pulmonary hypertension (JCS 2017\/JPCPHS 2017). Circ J 2019; 83: 842-945.","DOI":"10.1253\/circj.CJ-66-0158"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Akagi S, Nakamura K, Miyaji K, <i>et al<\/i>. Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension. Circ J 2010; 74: 2200-5.","DOI":"10.1253\/circj.CJ-10-0190"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tamura Y, Kumamaru H, Satoh T, <i>et al<\/i>. Effectiveness and outcome of pulmonary arterial hypertension-specific therapy in Japanese patients with pulmonary arterial hypertension. Circ J 2017; 82: 275-82.","DOI":"10.1253\/circj.CJ-17-0139"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Satoh M, Aso K, Nakayama T, Saji T. Effect of treatment with epoprostenol and endothelin receptor antagonists on the development of thyrotoxicosis in patients with pulmonary arterial hypertension. Endocr J 2017; 64: 1173-80.","DOI":"10.1507\/endocrj.EJ17-0155"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Shirai Y, Tamura Y, Yasuoka H, Satoh T, Kuwana M. IgG4-related disease in pulmonary arterial hypertension on long-term epoprostenol treatment. Eur Respir J 2014; 43: 1516-9.","DOI":"10.1183\/09031936.00144013"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Siu CW, Zhang XH, Yung C, Kung AW, Lau CP, Tse HF. Hemodynamic changes in hyperthyroidism-related pulmonary hypertension: a prospective echocardiographic study. J Clin Endocrinol Metab 2007; 92: 1736-42.","DOI":"10.1210\/jc.2006-1877"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Merce J, Ferr\u00e1s S, Oltra C, <i>et al<\/i>. Cardiovascular abnormalities in hyperthyroidism: a prospective Doppler echocardiographic study. Am J Med 2005; 118: 126-31.","DOI":"10.1016\/j.amjmed.2004.08.018"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Scicchitano P, Dentamaro I, Tunzi F, <i>et al<\/i>. Pulmonary hypertension in thyroid diseases. Endocrine 2016; 54: 578-87.","DOI":"10.1007\/s12020-016-0923-8"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Menon AA, Sahay S, Braverman LE, Farber HW. Thyroid dysfunction in patients with pulmonary artery hypertension (PAH): the effect of therapies affecting the prostanoid pathway. Lung 2019; 197: 761-8.","DOI":"10.1007\/s00408-019-00283-8"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Chemla D, Castelain V, Humbert M, <i>et al<\/i>. New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. Chest 2004; 126: 1313-7.","DOI":"10.1378\/chest.126.4.1313"},{"key":"15","unstructured":"15. Japan Thyroid Association. Guideline for the diagnosis of Graves&apos; disease. Available at: https:\/\/www.japanthyroid.jp\/en\/guidelines.html. Accessed April 1, 2025."},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Channick RN, Simonneau G, Sitbon O, <i>et al<\/i>. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-23.","DOI":"10.1016\/S0140-6736(01)06250-X"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Gali\u00e9 N, Badesch D, Oudiz R, <i>et al<\/i>. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 529-35.","DOI":"10.1016\/j.jacc.2005.04.050"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Gali\u00e8 N, Olschewski H, Oudiz RJ, <i>et al<\/i>. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010-9.","DOI":"10.1161\/CIRCULATIONAHA.107.742510"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Gali\u00e8 N, Ghofrani HA, Torbicki A, <i>et al<\/i>. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-57.","DOI":"10.1056\/NEJMoa050010"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Gali\u00e8 N, Brundage BH, Ghofrani HA, <i>et al<\/i>. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-903.","DOI":"10.1161\/CIRCULATIONAHA.108.839274"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Humbert M, Coghlan JG, Ghofrani HA, <i>et al<\/i>. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis 2017; 76: 422-6.","DOI":"10.1136\/annrheumdis-2015-209087"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sitbon O, Channick R, Chin KM, <i>et al<\/i>. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522-33.","DOI":"10.1056\/NEJMoa1503184"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Barst RJ, Oudiz RJ, Beardsworth A, <i>et al<\/i>. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2011; 30: 632-43.","DOI":"10.1016\/j.healun.2010.11.009"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Gr\u00fcnig E, Jansa P, Fan F, <i>et al<\/i>. Randomized trial of Macitentan\/Tadalafil single-tablet combination therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2024; 83: 473-84.","DOI":"10.1016\/j.jacc.2023.10.045"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Momoi M, Hiraide T, Shinya Y, <i>et al<\/i>. Triple oral combination therapy with macitentan, Riociguat, and selexipag for pulmonary arterial hypertension. Ther Adv Respir Dis 2021; 15: 1753466621995048.","DOI":"10.1177\/1753466621995048"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Tamura Y, Kumamaru H, Inami T, <i>et al<\/i>. Changes in the characteristics and initial treatments of pulmonary hypertension between 2008 and 2020 in Japan. JACC Asia 2022; 2: 273-84.","DOI":"10.1016\/j.jacasi.2022.02.011"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Pic P, Remy L, Mazzella E, Rua S. Cyclic AMP as the second hormonal messenger in the in vitro folliculogenesis of the foetal thyroid grand of the rat. Cell Tissue Res 1983; 232: 65-77.","DOI":"10.1007\/BF00222374"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Garmendia MA, Santos PS, Guill\u00e9n-Grima F, Galofr\u00e9 JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab 2014; 99: 923-31.","DOI":"10.1210\/jc.2013-2409"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Boswell MG, Zhou W, Newcomb DC, Peebles RS Jr. PGI2 as a regulator of CD4+ subset differentiation and function. Prostaglandins Other Lipid Mediat 2011; 96: 21-6.","DOI":"10.1016\/j.prostaglandins.2011.08.003"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Humbert M, Barst RJ, Robbins IM, <i>et al<\/i>. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-9.","DOI":"10.1183\/09031936.04.00028404"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Gr\u00fcnig E, Benjamin N, Lange TJ, <i>et al<\/i>. Safety, tolerability and clinical effects of a rapid dose titration of subcutaneous treprostinil therapy in pulmonary arterial hypertension: a prospective multi-centre trial. Respiration 2016; 92: 362-70.","DOI":"10.1159\/000450759"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/66\/3\/66_24-698\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T04:04:11Z","timestamp":1748664251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/66\/3\/66_24-698\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.24-698","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"type":"print","value":"1349-2365"},{"type":"electronic","value":"1349-3299"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"article-number":"24-698"}}